All In Biotech

Drug Trial Radar · NCT07852195

Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer

A Randomized Phase II/III Trial Evaluating Bipolar Androgen Therapy Followed by Darolutamide vs. Standard of Care in Patients With Metastatic Castration Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 432 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

432

Planned (sponsor's estimate)

Start

Jan 6, 2027

Primary completion

Mar 31, 2029

Study completion Mar 31, 2030

Sponsor

Lead sponsor
ECOG-ACRIN Cancer Research GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Oct 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II/II trial compares the effect of high dose testosterone followed by darolutamide with the usual care in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and keeps growing even when the amount of testosterone in the body is reduced to very low levels (castration-resistant). Usual care treatment for patients with metastatic prostate cancer includes surgery or medical castration which involves drugs to suppress the function of the testes. After receiving this therapy, a period of disease stability occurs, followed typically by cancer regrowth and castration-resistant disease. Castration-resistant prostate cancer occurs because the tumor cells are eventually able to adapt to the very low levels of testosterone in the body. A new type of therapy called Bipolar Androgen Therapy (BAT) involves giving patients very high doses of testosterone every 28 days. This results in a cycle of higher than normal testosterone levels (i.e., "supraphysiologic") to near castrate levels over the 28 days. BAT may be able to stop prostate tumor cells from becoming castrate-resistant. In this trial, patients who receive BAT with high dose testosterone and experience disease progression then receive darolutamide. Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Adding BAT with high dose testosterone prior to darolutamide after disease progression may help shrink or stabilize metastatic castration-resistant prostate cancer better than usual treatments alone.

Conditions

  • Metastatic Castration-Resistant Prostate Adenocarcinoma
  • Stage IVB Prostate Cancer AJCC v8

Interventions

  • Abiraterone AcetateDrug

    Given PO

  • Biospecimen CollectionProcedure

    Undergo biospecimen collection

  • Bone ScanProcedure

    Undergo bone imaging

  • CabazitaxelDrug

    Given IV

  • Computed TomographyProcedure

    Undergo CT

  • DarolutamideDrug

    Given PO

  • DexamethasoneDrug

    Given dexamethasone

  • DocetaxelDrug

    Given IV

  • EnzalutamideDrug

    Given PO

  • Lutetium Lu 177 Vipivotide TetraxetanDrug

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • MethylprednisoloneDrug

    Given methylprednisolone

  • PrednisoneDrug

    Given prednisone

  • Questionnaire AdministrationOther

    Ancillary studies

  • Testosterone CypionateDrug

    Given IM

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Second progression-free survival (PFS2) (Phase II)Time frame: From randomization to disease progression or death, whichever occurs first after initiation of second treatment (standard of care [SOC]2 or darolutamide), assessed up to 60 months
  2. Overall survival (OS) (Phase III)Time frame: From randomization until death from any cause or date last known alive, assessed up to 60 months
  3. Overall quality of life (QOL)Time frame: At randomization,12, 24 and 48 weeks after randomization

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.